356 related articles for article (PubMed ID: 24239753)
1. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Bast RC; Thigpen JT; Arbuck SG; Basen-Engquist K; Burke LB; Freedman R; Horning SJ; Ozols R; Rustin GJ; Spriggs D; Wenzel LB; Pazdur R
Gynecol Oncol; 2007 Nov; 107(2):173-6. PubMed ID: 17950384
[TBL] [Abstract][Full Text] [Related]
3. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.
Herzog TJ; Alvarez RD; Secord A; Goff BA; Mannel RS; Monk BJ; Coleman RL
Gynecol Oncol; 2014 Oct; 135(1):3-7. PubMed ID: 25124162
[TBL] [Abstract][Full Text] [Related]
4. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
5. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
Matulonis UA; Oza AM; Ho TW; Ledermann JA
Cancer; 2015 Jun; 121(11):1737-46. PubMed ID: 25336142
[TBL] [Abstract][Full Text] [Related]
6. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
Herzog TJ; Ison G; Alvarez RD; Balasubramaniam S; Armstrong DK; Beaver JA; Ellis A; Tang S; Ford P; McKee A; Gershenson DM; Kim G; Monk BJ; Pazdur R; Coleman RL
Gynecol Oncol; 2017 Oct; 147(1):3-10. PubMed ID: 28844539
[No Abstract] [Full Text] [Related]
7. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
8. Meaningful endpoints for therapies approved for hematologic malignancies.
Smith BD; DeZern AE; Bastian AW; Durie BGM
Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
[TBL] [Abstract][Full Text] [Related]
9. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
11. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
12. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
13. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M;
Eur J Cancer; 2017 Jun; 78():133-138. PubMed ID: 28448857
[TBL] [Abstract][Full Text] [Related]
14. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
15. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P
Lancet Oncol; 2021 May; 22(5):632-642. PubMed ID: 33862001
[TBL] [Abstract][Full Text] [Related]
16. Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021.
Alabaku O; Laffey TN; Suh K; Li M
J Manag Care Spec Pharm; 2022 Nov; 28(11):1219-1223. PubMed ID: 36282934
[No Abstract] [Full Text] [Related]
17. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.
Oza AM; Castonguay V; Tsoref D; Diaz-Padilla I; Karakasis K; Mackay H; Welch S; Weberpals J; Hoskins P; Plante M; Provencher D; Tonkin K; Covens A; Ghatage P; Gregoire J; Hirte H; Miller D; Rosen B; Maroun J; Buyse M; Coens C; Brady MF; Stuart GC
Curr Oncol; 2011 Oct; 18 Suppl 2(Suppl 2):S20-7. PubMed ID: 21969808
[TBL] [Abstract][Full Text] [Related]
19. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance.
Minion LE; Coleman RL; Alvarez RD; Herzog TJ
Gynecol Oncol; 2016 Feb; 140(2):193-8. PubMed ID: 26631607
[TBL] [Abstract][Full Text] [Related]
20. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
